Craig-Hallum bullish on MapLight Therapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $43 price target The firm views MapLight as a differentiated muscarinic setup where the key debate is no longer whether M1/M4 agonism works, but which programs can deliver the best real-world persistence and tolerability. Craig-Hallum believes ML-007C-MA is one of the more interesting next-gen muscarinic approaches given its exposure-synchronization strategy designed to reduce GI burden, down-dosing, and treatment interruption that may ultimately limit first-generation therapies in commercial use. It views the setup into upcoming Phase 2 schizophrenia data in Q3 2026 as attractive given the potential for meaningful rerating if MapLight demonstrates clear clinical differentiation on tolerability and persistence.